問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Division of Urology

Division of Thoracic Medicine

National Taiwan University Hospital Hsin-Chu Branch (在職)

Division of Hematology & Oncology

National Taiwan University Cancer Center (在職)

Division of Hematology & Oncology

Division of Hematology & Oncology

更新時間：2025-09-17

林家齊Lin, Chia-Chi
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

Recruiting Trial

377Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林家齊

List

688Cases

2024-08-01 - 2029-09-06

Phase III

Active
A randomized, multicenter, double-blind, Phase 3 study to investigate the safety and efficacy of belrestotug in combination with dostarlimab compared with placebo in combination with pembrolizumab in participants with previously untreated, unresectable, locally advanced or metastatic PD-L1-selected non-small-cell lung cancer (GALAXIES LUNG-301)

  • Condition/Disease

    previously untreated, unresectable, locally advanced or metastatic PD-L1-selected non-small-cell lung cancer (GALAXIES LUNG-301)

  • Test Drug

    injection injection injection

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2025-06-18 - 2027-12-31

Phase I

Not yet recruiting
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of GSK5764227 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

  • Condition/Disease

    Neoplasms

  • Test Drug

    注射劑

Participate Sites
6Sites

Recruiting6Sites

2020-04-01 - 2028-12-31

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2022-02-01 - 2028-01-31

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2026-01-01 - 2030-12-31

Others

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2023-03-19 - 2026-03-16

Phase I

Active
A Phase 1, Open-label, Multi-center, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of HCB101 in Subjects with Advanced Solid Tumors or Relapsed and Refractory non-Hodgkin Lymphomas

  • Condition/Disease

    Advanced Solid Tumors or Relapsed and Refractory non-Hodgkin Lymphomas

  • Test Drug

    injection

Participate Sites
3Sites

Recruiting3Sites

2025-11-01 - 2027-12-31

Phase I

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-12-01 - 2027-12-31

Phase II

Active
A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC)

  • Condition/Disease

    Non-Small Cell Lung Cancer (NSCLC)

  • Test Drug

    injection

Participate Sites
10Sites

Recruiting10Sites

2017-05-01 - 2021-09-01

Phase II

Completed
A Randomized, Open-label (formerly Double-blind), Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination with Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment

  • Condition/Disease

    Renal Cell Carcinoma

  • Test Drug

    Lenvima Capsules 4 mg, 10 mg

Participate Sites
5Sites

Terminated4Sites

2023-12-01 - 2028-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

1 13 14 15 16 17 69
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB